selected publications
-
conference proceeding
- Safety of XT-150 Human IL-10v Plasmid Gene Therapy Intrathecal in a Mouse Neuropathic Pain Model. Molecular Therapy. 200-200. 2017
-
journal article
-
Toll -like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.
Brain, Behavior, and Immunity.
80-95.
2021
-
Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.
Behavioural Brain Research.
2021
-
Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.
Pain.
2634-2640.
2019
-
Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling.
The FASEB Journal.
9577-9587.
2019
-
A single peri-sciatic nerve administration of the adenosine 2A receptor agonist ATL313 produces long-lasting anti-allodynia and anti-inflammatory effects in male rats.
Brain, Behavior, and Immunity.
116-125.
2019
-
Sustained reversal of central neuropathic pain induced by a single intrathecal injection of adenosine A2A receptor agonists.
Brain, Behavior, and Immunity.
470-479.
2018
-
Prior voluntary wheel running attenuates neuropathic pain.
Pain.
2012-2023.
2016
-
The therapeutic potential of interleukin-10 in neuroimmune diseases.
Neuropharmacology.
55-69.
2015
-
Toll -like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.
Brain, Behavior, and Immunity.
80-95.
2021